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ABSTRACT The central theme in prion diseases is the conformational transition of a cellular protein from a physiologic to
a pathologic (so-called scrapie) state. Currently, two alternative models exist for the mechanism of this autocatalytic process;
in the template assistance model the prion is assumed to be a monomer of the scrapie conformer, whereas in the nucleated
polymerization model it is thought to be an amyloid rod. A recent variation on the latter assumes disulfide reshuffling as the
mechanism of polymerization. The existence of stable dimers, let alone their mechanistic role, is not taken into account in
either of these models. In this paper we review evidence supporting that the dimerization of either the normal or the scrapie
state, or both, has a decisive role in prion replication. The contribution of redox changes, i.e., the temporary opening and
possible rearrangement of the intramolecular disulfide bridge is also considered. We present a model including these features
largely ignored so far and show that it adheres satisfactorily to the observed phenomenology of prion replication.
INTRODUCTION
The transmissible spongiform encephalopathies (TSEs), or
prion diseases, are neurodegenerative disorders which can
be either transmissible, inherited, or sporadic (Weissmann,
1996; Prusiner, 1998; Horiuchi and Caughey, 1999). Over-
whelming evidence supports that all three forms (as stated
by the “protein only” hypothesis) are mechanistically united
by the conversion of a host-encoded protein (PrPc) to an
altered conformation, the scrapie state (PrPsc). In compli-
ance with the genesis of the disease, the initial structural
change may be caused by either the transmission of the
pathologic prion, a germ-line mutation of its gene, or a
chance conformational transition. The subsequent propaga-
tion of the scrapie state follows the same path irrespective of
the initial event. Currently, there are two basically different
models for describing the mechanism of scrapie replication
(Bamborough et al., 1996; Cohen and Prusiner, 1998; Ho-
riuchi and Caughey, 1999). In the template assistance model
PrPsc is considered more stable than PrPc, and the confor-
mational transition is an autocatalytic process which occurs
via the transient interaction of PrPc with PrPsc. In the
nucleated polymerization model, PrPsc as a monomer is
intrinsically unstable and can only arise because of multiple
stabilizing interactions with an amyloid polymer.
A recent variety of the latter is based on the assumption
that the prion polymer is linked by intermolecular disulfide
bonds (Welker et al., 2001); i.e., disulfide reorganization is
essential to PrPsc generation. All three models rely on
significant experimental evidence and exhibit the basic tem-
poral aspects of the disease: the long and uniform incuba-
tion time and initial exponential growth of infectious titer
(Bamborough et al., 1996; Horiuchi and Caughey, 1999). It
seems that our current knowledge does not allow an un-
equivocal decision between them.
This ambiguity in delineating the structural transition
largely stems from the uncertainty in defining what the
infectious form of PrP is. Various protocols of PrPsc isola-
tion yield different preparations, the relation of which to the
infectious agent is not clear. The most noted forms are: 1)
fibrillar amyloid prion rods, which are infectious and form
from protease-resistant PrP27–30; 2) ordered, nonfibrillar
aggregates which are also infectious but are not amyloid by
the criterion of Congo Red binding; and 3) amorphous
aggregates which show fibrillar structure but are less pro-
tease-resistant than the previous ones and are not infectious
(Bamborough et al., 1996; Cohen and Prusiner, 1998;
Prusiner, 1998). The above polymerization models can only
be applied to the rods; as discussed later, significant evi-
dence supports that no higher aggregates are needed for
infectivity (Bamborough et al., 1996). A further crucial
point is that the ratio of the infectious unit to PrPsc mole-
cules is only 1:100,000 in prion preparations (Bolton et
al., 1991; Weissmann et al., 1996); thus, the structure of the
infectious molecule can not be identified, which allows for
various models of its structure and propagation.
Pertinent to this issue is that under nonphysiologic con-
ditions most globular proteins have a tendency to convert to
a high -sheet form that polymerizes into an insoluble
amyloid (Dobson, 1999; Taubes, 1996). This is rarely seen
under physiologic conditions but with the prion protein it
does occur when its native form contacts the scrapie form.
As we have pointed out, this peculiar behavior probably
originated in an evolutionary change when PrP, previously
an integral membrane protein, got expelled to the extracel-
lular space (Tompa et al., 2001). In our view, this resulted
in multiple stable conformations of PrP which, because of
functional constraints (Tompa and Friedrich, 1998), has
never reached a state where the amino acid sequence en-
codes a single three-dimensional (3-D) structure. This
unique property might manifest itself in the formation of a
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polymer that differs from other amyloids in that it is trans-
missible.
Neither of the current propagation mechanisms, however,
attributes a crucial role to the dimer of either PrP form,
although the idea of dimerization appeared very early in the
prion literature (Dickinson and Outram, 1979) and relies on
considerable experimental data (Cohen and Prusiner, 1998).
In this paper we review evidence compatible with the idea
that both dimer formation and redox changes play a role in
prion replication. Based on these inferences, a model is
presented, which incorporates these mechanistic elements.
It is shown that this model describes the time course of
disease progression satisfactorily and occupies an interme-
diary position between the two classical alternatives that
attribute either strictly kinetic or thermodynamic control to
the propagation of the scrapie state.
Evidence for dimer formation
Genetic studies of scrapie pathogenesis led to the original
proposal that dimers might be important in scrapie replica-
tion (Dickinson and Outram, 1979). Here we survey evi-
dence for dimer formation in three sections: first, it is shown
that a large oligomer (amyloid) is not needed for infectivity;
second, indirect evidence is compiled; and third, direct
evidence under both physiologic and pathologic conditions
is discussed.
The first pertinent observation is that although amyloid
formation often accompanies prion disease, the pathologic
state frequently develops without fibril deposition (Bambo-
rough et al., 1996; Prusiner, 1998). Further, isolated amy-
loids are not necessary for infectivity, and have been shown
to be artifacts generated by proteolytic processing during
PrPsc purification (McKinley et al., 1991; Wille et al.,
1996). In fact, amyloid prion rods can be dispersed into
detergent-lipid-protein complexes and transferred into lipo-
somes with a significant, 10- (Gabizon et al., 1987) to
100-fold (Gabizon et al., 1988) increase in infectivity. In
addition, such highly infectious preparations could be made
without an intermediate amyloid formation, by direct solu-
bilization of membrane-bound PrPsc. Infectivity can be un-
coupled from the amyloid fibril organization of prion rods
(Wille et al., 1996), and protease resistance is seen both
without low solubility and amyloid formation (Muramoto et
al., 1996).
Thus, several observations suggest that the infectious unit
is not a polymer. As for its exact size, infectivity has been
found to be associated with a wide size range of aggregates,
but not with monomers (Prusiner et al., 1993; Hope, 1994;
Caughey et al., 1997). To be more specific, several obser-
vations indicate that PrP can form dimers, both in its phys-
iologic and pathologic state. First, transgenic studies on the
species specificity of prion replication have shown that PrPc
transiently interacts with PrPsc in the conversion process
(Prusiner et al., 1990). As the interaction requires their
sequence similarity or identity, the existence of such a
heterodimer possibly reflects the natural tendency of PrPc
for homodimerization. Based on such observations, a low-
resolution model of the homodimer (Warwicker and Gane,
1996), and later also of the heterodimer based on -stacking
(Warwicker, 1997) has been created. The model was further
extended to explain prion propagation by assuming addition
of dimers through hairpin stacking (Warwicker, 2000).
From structural considerations it was inferred that addition
of dimers is much favored over monomers, as these stabilize
the -hairpin core suggested, in accord with the -helix3
-sheet conversion that underlies PrPsc formation (Pan et
al., 1993). This theoretical model building has also received
support from thermodynamic considerations. A simple lat-
tice model revealed that model proteins, which are less
stable in the monomeric state, are susceptible to the forma-
tion of alternative native states as homodimers (Harrison et
al., 1999). Physical studies have suggested that PrPsc is
more stable than PrPc (James et al., 1997; Zhang et al.,
1997).
In addition to indirect evidence, models, and calculations,
there is also substantial direct evidence for PrP dimerization
under physiologic and pathologic conditions. PrP in brain
homogenates, but not recombinant PrP, were observed by
various techniques to form dimers (Meyer et al., 2000); this
behavior was attributed to either glycosylation or an as-yet
unidentified accessory protein, known to be involved in the
PrPc-PrPsc interaction (Telling et al., 1995; Kaneko et al.,
1997). In contrast, recombinant PrP(90–231) under the con-
ditions used for NMR studies forms dimers for a measurable
fraction of time (James et al., 1997). In crystallographic
studies, human PrP has a domain-swapped dimer structure
in which the disulfide bonds are rearranged and occupy an
intermolecular position (Knaus et al., 2001). A 54-kDa
normal cellular protein, possibly a cross-linked PrPc dimer,
was observed in uninfected hamster and mouse brains
(Bendheim and Bolton, 1986). In murine neuroblastoma
cells expressing hamster PrP, a similar 60-kDa protein was
seen and shown to be a covalently cross-linked PrP dimer
(Priola et al., 1995). This protein was protease-sensitive,
formed larger aggregates, and in a cell-free conversion
system, it could be converted to a protease-resistant form
(Kocisko et al., 1994); this is thought to be an appropriate in
vitro model of scrapie generation. Thus, this dimer dis-
played both normal and disease-associated attributes, indi-
cating that it might represent a dimeric intermediate state in
prion formation. Scrapie dimers have also been reported in
infected brain samples. Protease-resistant PrP dimers were
observed in hamster brain upon gentle disaggregation (Skla-
viadis et al., 1989) or after large-scale purification (Turk et
al., 1988). In an earlier work (Bellinger-Kawahara et al.,
1988), inactivation of scrapie prions by ionizing radiation
exhibited a target size of 55 kDa under various conditions,
i.e., in brain homogenates, detergent-extracted microsomes,
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or purified amyloid rods. All these data argue for the prev-
alence of a dimeric PrP form in the infective species.
A final, general comment on dimer formation is that
dimerization is the most ancient and common step in the
evolution of oligomeric proteins (Monod et al., 1965). In an
isologous dimer, the same binding sets on two subunits
(protomers) complement one another, for which the two
protomers have to be rotated 180° relative to one another. In
heterologous dimers two different binding sets on the pro-
tomer surface bind one another; this type of association may
give rise to closed structures of cyclic symmetry or long,
open polymers. Furthermore, domain swapping, observed
for human PrP (Knaus et al., 2001) and many other proteins
(Bennett et al., 1995; Janowski et al., 2001) is a general
mechanism for dimerization and oligomerization, thought to
be implicated in both the evolution of oligomeric proteins
and fiber formation in amyloidoses.
Disulfide rearrangement in the
PrPc 3 PrPsc conversion
The conversion of PrPc to PrPsc is thought to occur without
the covalent modification of the protein (Pan et al., 1993;
Stahl et al., 1993). Recent data, however, suggest one ex-
ception: the possible rearrangement of the sole disulfide
bond of mature prion protein (Welker et al., 2001).
At first sight the disulfide bridge Cys179-Cys214 (ham-
ster numbering) of PrP seems protected from such in-
sults. The 3-D structure of PrPc determined by NMR
(Riek et al., 1997; Lopez Garcia et al., 2000; Zahn et al.,
2000) shows that this disulfide is buried within the stable
hydrophobic core of the protein. Further, both PrPc and
PrPsc contain an intact, apparently intramolecular disul-
fide bridge (Turk et al., 1988), i.e., the conversion pre-
serves the disulfide bond. In addition, the conversion
process was effectively inhibited by reducing agents such
as 2.5 mM dithiothreitol (DTT) in a cell-free system
(Herrmann and Caughey, 1998), and the mutation C179A
prevented the formation of a protease-resistant, scrapie-
like state of ectopic PrP in a scrapie-infected neuroblas-
toma cell line (Muramoto et al., 1996). Thus, the disul-
fide bridge seems to be indispensable for the transition
into the scrapie state.
Other observations, however, suggest that a metastable
intermediate with its disulfide bridge temporarily broken
can not be excluded. The C179A mutant expressed in
uninfected CHO cells suffered from severe subcellular
trafficking abnormalities which probably resulted from
its aggregation in the early secretory pathway (Yanai et
al., 1999). Thus, its inability to produce PrPsc in scrapie-
infected cells could be attributable to improper cellular
processing and not to the lack of a disulfide bond per se.
The inhibition of PrPsc formation in vitro is also reveal-
ing. As noted, the intramolecular disulfide bridge in PrP
is very rigid (Hosszu et al., 1999) and is not accessible to
reducing agents (Maiti and Surewicz, 2001). At pH 8.0,
its reduction requires denaturing conditions such as 6.0
M GuHCl and high concentration (100 mM) of DTT
(Jackson et al., 1999; Maiti and Surewicz, 2001). At
lower pH (6.0), known to favor structural transitions of
PrP toward the scrapie state (Taraboulos et al., 1992;
Borchelt et al., 1992; Jackson et al., 1999; Maiti and
Surewicz, 2001), a lower DTT concentration (1–2 mM)
under milder conditions (1.0 M GuHCl) is sufficient to
reduce it and inhibit its conversion to a scrapie-like
protease-resistant state (PrPres). Possibly, under condi-
tions which favor structural transition (i.e., lower pH,
slight denaturation, the presence of PrPres) the disulfide
bridge is sensitive to reduction and is more accessible
than otherwise. A plausible explanation is to assume a
metastable intermediate with its structure partially un-
folded. For example, reduced and mildly acidified PrP
was found to switch between its native conformation and
a partially protease-resistant, -rich amyloidogenic state
(Jackson et al., 1999) under conditions probably encoun-
tered in vivo when PrPsc formation occurs in endosomes
or lysosomes (Taraboulos et al., 1992; Borchelt et al.,
1992; Aguzzi and Weissmann, 1997). In refolding studies
with recombinant hamster PrP, the native -helical struc-
ture appeared only after formation of the intramolecular
disulfide bond, whereas a scrapie-like, -rich form was
accessible both with and without the disulfide bond
(Mehlhorn et al., 1996); in thermal denaturation studies
the -helical form rapidly converted into the thermody-
namically more stable -sheet form (Zhang et al., 1997).
In a mutagenesis study the C179A mutant folded into a
stable monomeric form only under mildly acidic condi-
tions; at a slightly higher ionic strength, these structures
underwent a transition to a -rich state and oligomeriza-
tion (Maiti and Surewicz, 2001). As a final note, the
human PrP dimer has its disulfides rearranged into inter-
molecular bonds (Hosszu et al., 1999), which shows that
disulfide reshuffling may be involved in dimerization/
polymerization leading to PrPsc formation.
Thus, redox changes during the transition to the scrapie
state can not be discounted. The imbalance of either of the
multiple redox sytems within the cell might also contribute
by upsetting the redox state of PrP. For example, the thi-
oredoxin/thioredoxin reductase system could reduce PrP
with an immediate increase in -sheet content and a parallel
diminution in solubility (Requena and Levine, 2001). An-
other candidate is homocysteine; as in Alzheimer disease,
its level correlates with the progress of the disease (Clarke
et al., 1998). This was interpreted in terms of homocysteine
contributing the free thiol needed for thiol-disulfide inter-
change involved in amyloid formation (Schweers et al.,
1995).
Such observations have led to the proposal that disul-
fide rearrangement, i.e., a transiently reduced intermedi-
ate, plays a role in the structural transition to the scrapie
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state (Mehlhorn et al., 1996). In one mechanistic scheme,
the disulfide bridge may break down temporarily because
of thiol-disulfide rearrangement catalyzed by a free thiol
group (Feughelman and Willis, 2000). Thus, the -helical
cluster becomes unstable and rearranges into a -hairpin
structure, which is further stabilized by the disulfide
bond that reforms in the reversal of the exchange reac-
tion. In a possible alternative model, a related mechanism
is assumed, but the catalytic thiol is thought to be pro-
vided by the terminal free Cys of a PrPsc polymer
(Welker et al., 2001). In this model the initial thiolate
attack is facilitated by the association of a PrPc monomer
and the PrPsc polymer, which ensures high effective
concentration of the thiol group and destabilizes the
tertiary fold of PrPc. The novel disulfide bond thus cre-
ated brings together the respective parts of the two mol-
ecules, initiating the structural transition to the -fold
characteristic of the scrapie state. This disulfide reshuf-
fling can also proceed the other way, which may explain
the dissociation of PrP monomers with an intact disulfide
bond from PrPsc aggregates upon denaturation (Welker et
al., 2001).
As it appears from all the foregoing considerations, the
disulfide bond and hydrophobic packing are tightly linked
in maintaining the native fold of PrP; for the structural
transition probably both have to break down. This scenario
can be supported by two further considerations. First, mu-
tations involved in inherited forms of prion diseases are
often seen to destabilize PrP structure (Swietnicki et al.,
1998; Liemann and Glockshuber, 1999), thus increasing the
relative abundance of a putative metastable intermediate.
Second, the preferred oxidation state and the ability of a
cysteine for disulfide formation can be estimated on the
basis of its conservation in homologous proteins and se-
quential environment. As calculated according to Fiser et al.
(1992), both Cys179 and Cys214 are highly conserved, which
indicates their tendency to exist in an oxidized form. Pre-
dicting their disulfide-forming ability according to Fiser and
Simon (2000), however, suggests only an intermediate po-
tential for Cys179 (0.49) and a low potential for Cys214
(0.049). This latter value indicates 10% probability for
Cys214 to be involved in a disulfide bond. One reason for
this low value is the lack of a Gly in its vicinity; this residue
would make the chain more flexible and enable it to adopt
the correct conformation demanded by the covalent bond
between the two cysteines. Although the two Cys residues
are separated by 30 amino acids, this intervening segment
is highly structured, which may cause structural constraints.
As the disulfide bond in PrPc is located within an extremely
stable region of the hydrophobic core (Hosszu et al., 1999),
probably a range of very favorable interactions compensate
for the lack of glycines; this gives an overall stability to the
disulfide bond despite its non-ideal sequential environment.
Nevertheless, for an intermolecular disulfide bond within a
-structure, segmental flexibility is less important because
of the higher degree of freedom of the system of two
separate molecules. Consequently, the strain of the disulfide
bond in the native -helical structure may be relieved,
providing increased stability to the proposed intermolecular
bond.
Dimerization model of PrPsc replication
Taken together, all the above data and considerations un-
derline that PrP dimerization and disulfide rearrangement
may play a significant role in the propagation of the scrapie
state. So far, these details only implicitly appeared in mech-
anistic models; based on the evidence presented here, we
propose a model of scrapie replication in which these ele-
ments play a fundamental role.
The basic element of our model is that PrPsc is a dimer
with stabilizing intermolecular disulfide bridges (Fig. 1).
Replication of this scrapie state begins with recruiting a
normal PrPc dimer, with native intramolecular disulfide
bonds. The binding energy within this dimer of dimers
loosens the native fold of PrPc dimer and destabilizes its
intramolecular disulfide bonds. Within this transient, par-
tially unfolded structure, disulfide rearrangement occurs
and results in novel, intermolecular disulfide bridges. Be-
cause of these bonds, the transient structure relaxes into the
-rich scrapie conformation which draws its stability from
the mutual reinforcement of the -sheet structure and the
covalent bond. The newly formed scrapie dimer then dif-
fuses away, enabling a new catalytic cycle to commence.
This model mixes features of kinetic and thermodynamic
control prominent in previous models, in that the scrapie
dimer is a catalytic unit resembling the monomer in the
template assistance model, whereas the binding energy and
intermolecular disulfide bridges within a dimer add to sta-
bilization of the scrapie conformer, just as an amyloid in the
nucleated polymerization model would. The concentration
of prion (PrPsc) and all other species in the model obeys the
kinetic equations formulated in Scheme 1. Solution of this
differential equation system yields the time course of
scrapie replication. As seen in Fig. 2, our model describes
the kinetics of scrapie replication adequately as it accounts
for the long incubation time and the exponential growth of
infectivity (trace A). Species barrier is also easily demon-
strated: a slight decrease in the rate constant of PrPsc-PrPc
interaction delays appearance of the scrapie state signifi-
cantly (Fig. 2, trace B).
Analogies in other diseases
As a final corroboration of the view elaborated in this paper,
we shortly discuss four analogous cases of related phenom-
ena or diseases. These examples constitute a good precedent
for the feasibility of the model proposed for prion replica-
tion in TSEs.
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The first example is the tendency of a yeast prion for
dimerization. In yeast, inheritance of certain non-Mendelian
genetic elements is associated with the prion-like propagation
of the altered conformation of normal cytosolic proteins
(Wickner et al., 1999; True and Lindquist, 2000). One of these,
Ure2, is involved in the regulation of nitrogen metabolism; its
altered conformation results in a stable phenotype that can be
passed on to the progeny. Recently, the recombinant protein
was shown to be a dimer both in solution (Perrett et al., 1999)
and in crystals (Bousset et al., 2001). Incidentally, Ure2 has a
domain organization similar to mammalian PrP as it can be
separated into globular and unstructured halves (Lopez Garcia
et al., 2000; Zahn et al., 2000).
As a second example, human cystatin C is cited. This
potent inhibitor of cysteine proteases contributes to amyloid
formation in amyloid angiopathy of elderly people; its point
mutation causes massive amyloidosis, cerebral hemorrhage,
and death in young adults. The crystal structure of this
protein reveals dimers which form via 3-D domain swap-
ping; it is suggested that a similar mechanism may account
for amyloid formation in the disease (Janowski et al., 2001).
The third and fourth examples are related to both
dimerization and disulfide reorganization. Prion diseases
show significant analogy to Alzheimer disease, a neuro-
degenerative disorder with similar lesions in the central
nervous system (Iqbal and Grundke-Iqbal, 1996). One
hallmark of Alzheimer’s disease is the pathologic aggre-
gation of , a neuron-specific microtubule-associated
protein, into paired helical filaments within degenerating
neurones. Studies with single-Cys  constructs have
shown that the formation of  dimers linked by intermo-
lecular disulfide bonds is essential for amyloid formation
(Schweers et al., 1995); two-Cys constructs formed com-
pact monomers with intramolecular disulfide bridges and
could not nucleate paired helical filaments formation.
Familial British dementia, in contrast, is also a neurode-
generative disorder which shares some features, most
notably the deposition of amyloid, with TSEs. In this
disease amyloids arise from a peptide fragment of a
larger precursor protein (El-Agnaf et al., 2001). It has
been demonstrated that the formation of a disulfide
bridge is essential for dimerization of the peptide; dimer-
FIGURE 1 Replication of the scrapie state based on dimer formation and disulfide rearrangement. The figure is a schematic rendering of a PrPc3 PrPsc
conversion model based on both dimer formation and disulfide rearrangement. It is assumed that PrPsc is a dimer of predominantly -structure, stabilized
by two intermolecular disulfide bridges. The critical step in replication is the recruitment of a PrPc dimer with an -helical structure. Upon binding, the
structure of PrPc dimer unfolds to a large extent; within this transient structure the disulfide bonds open up and reform in an intermolecular fashion. This
initiates the structures to collapse into the more stable scrapie state with prevailing -sheet(s). The newly formed scrapie dimer either diffuses away or
remains in place, serving as a seed for amyloid.
FIGURE 2 Time course of scrapie replication by dimerization-disulfide
rearrangement. Calculations based on the kinetic scheme (Scheme 1)
demonstrate that scrapie replication based on the dominant role of dimer
formation and disulfide rearrangement adequately describes the observed
time course of the increase of infectivity in prion diseases. This includes a
significant incubation period (lag phase) in the infectious unit reaching an
appreciable level and an exponential growth in the initial phase of the
disease. The initial concentrations and rate constants used in solving the
kinetic equations were as follows: [PrPsc], 107 M; [PrPc], 1 M; kon, 6 
103 M1day1 (A) or 4  103 M1day1 (B); koff, 2  102 day1; ktr,
1 day1; kd, 1 day1. As seen, a slight weakening of the PrPsc-PrPc
interaction causes a significant delay in the conversion to the scrapie state.
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ization, in turn, was found necessary for the elongation of
oligomers and formation of fibrils.
CONCLUSION
The model presented in this paper attempts to reconcile
dimerization of PrP and disulfide reshuffling with other
aspects of scrapie replication; its details are consistent with
a range of observations not incorporated into mechanistic
models so far. Its inferences are testable by carefully
planned experiments and, we hope, will deepen our under-
standing of the unorthodox phenomenon of propagation of
an altered protein state. This bears the promise of conceiv-
ing novel therapeutic strategies against the so far fatal prion
diseases.
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